Cost-effectiveness and socioeconomic implications of prevention and management of chronic kidney disease in type 2 diabetes
- 1 April 2010
- journal article
- practice guideline
- Published by Wiley in Nephrology
- Vol. 15 (s1), S195-S203
- https://doi.org/10.1111/j.1440-1797.2010.01241.x
Abstract
No abstract availableThis publication has 38 references indexed in Scilit:
- Socioeconomic Status and Chronic Kidney Disease at Presentation to a Renal Service in the United KingdomClinical Journal of the American Society of Nephrology, 2008
- Socioeconomic Disadvantage and Kidney Disease in the United States, Australia, and ThailandAmerican Journal of Public Health, 2008
- Characteristics and outcome of type 2 diabetes in urban Aboriginal people: the Fremantle Diabetes StudyInternal Medicine Journal, 2006
- Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney diseaseEmergencias, 2006
- Albuminuria is evident in the early stages of diabetes onset: Results from the Australian diabetes, obesity, and lifestyle study (AusDiab)American Journal of Kidney Diseases, 2004
- Social Inequality: Utilisation of general practitioner services by socio‐economic disadvantage and geographic remotenessAustralian and New Zealand Journal of Public Health, 2004
- Burden of end-stage renal disease among indigenous peoples in Australia and New ZealandKidney International, 2003
- Feasibility study of the early detection and treatment of renal disease by mass screeningInternal Medicine Journal, 2002
- An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54)Diabetic Medicine, 2001
- Direct Medical Costs of Complications Resulting From Type 2 Diabetes in Hie U.S.Diabetes Care, 1998